Alnylam Pharmaceuticals
ALNY
#728
Rank
A$48.74 B
Marketcap
A$364.31
Share price
2.55%
Change (1 day)
-46.93%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): A$5.61

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$5.39. In 2025 the company made an earnings per share (EPS) of A$2.56.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$5.61118.89%
2025A$2.56
2023A-$5.02-62%
2022A-$13.2229.03%
2021A-$10.25-3.36%
2020A-$10.60-8.48%
2019A-$11.597.67%
2018A-$10.7639.74%
2017A-$7.7012.94%
2016A-$6.8238.84%
2015A-$4.91-32.88%
2014A-$7.32259.44%
2013A-$2.04-31.25%
2012A-$2.96

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
A$9.99 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$3.64-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$60.53 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$0.81-115.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.04-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.38-107.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$1.95-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A$1.15-78.63%๐Ÿ‡บ๐Ÿ‡ธ USA